Results 171 to 180 of about 428,471 (322)

TREX1, a predator for treating MSI‐H tumors?

Molecular Oncology, EarlyView.
Immunotherapy benefits many patients; yet, some with MSI‐H tumors remain unresponsive despite their high immunogenicity. Xu et al. reveal that TREX1 enables immune evasion by degrading cytosolic DNA and suppressing cGAS–STING–IFN‐I signaling. TREX1 loss restores DNA sensing, increases CD8+ T and NK cell infiltration, and boosts antitumor immunity ...
Elena Benidovskaya, Joséphine Deneft, Marc Van den Eynde   +2 more
wiley   +1 more source

CARE-DN: An Extension of the CARE Guidelines for Dry Needling Case Reports. [PDF]

Cureus
Tzigkounakis G, Simati K, Georgiadis K, Kostaridou V, Battersby P, Calvo S, Herrero P, Kuzdzal A, McEvoy J, Sánchez Milá Z, Velázquez Saornil J, Voight M, Wang T, Stefanakis M.   +13 more
europepmc   +1 more source

Brand extensions into the hospitality industry by luxury fashion labels and national identity: the cases of Hotel Missoni Edinburgh and Maison Moschino [PDF]

, 2014
Alice Dallabona
openalex  

An exploratory qualitative study of brand associations as a means for brand extensions : Part 1

, 2014
Hans Kasper, Y Strepp, NS Terblanche
openalex   +2 more sources

A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy

Molecular Oncology, EarlyView.
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti, Giovanni Germano, Pietro Paolo Vitiello, Alberto Bardelli   +3 more
wiley   +1 more source

Semiautomatic mapping of a national drug terminology to standardised OMOP drug concepts using publicly available supplementary information. [PDF]

BMC Med Res Methodol
Katsch F, Mészáros Á, Héja T, Hussein R, Duftschmid G.   +4 more
europepmc   +1 more source

More than Fit: Brand Extension Authenticity (Web Appendix) [PDF]

, 2012
Susan Spiggle, Hang T. Nguyen, Mary Caravella   +2 more
openalex  

The analysis of effective factors on product brand image after extension (PBI) in home appliance industry in Iran

, 2012
Hassan Ghorbani
openalex   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

Policy Without Penalty: A Review of Pediatric Research Equity Act Noncompliance Letters. [PDF]

Pediatrics
Green DJ, Pagano A, Goldman J, Deshmukh AD.   +3 more
europepmc   +1 more source